HomeCompareBRLAF vs MRK

BRLAF vs MRK: Dividend Comparison 2026

BRLAF yields 6.64% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $34.3K in total portfolio value
10 years
BRLAF
BRLAF
● Live price
6.64%
Share price
$4.61
Annual div
$0.31
5Y div CAGR
-27.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.5K
Annual income
$30.03
Full BRLAF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — BRLAF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRLAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRLAF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRLAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRLAF
Annual income on $10K today (after 15% tax)
$564.74/yr
After 10yr DRIP, annual income (after tax)
$25.53/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,302.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRLAF + MRK for your $10,000?

BRLAF: 50%MRK: 50%
100% MRK50/50100% BRLAF
Portfolio after 10yr
$39.6K
Annual income
$4,914.09/yr
Blended yield
12.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BRLAF
No analyst data
Altman Z
1.5
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRLAF buys
0
MRK buys
0
No recent congressional trades found for BRLAF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRLAFMRK
Forward yield6.64%2.76%
Annual dividend / share$0.31$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27.6%32.7%
Portfolio after 10y$22.5K$56.8K
Annual income after 10y$30.03$9,798.13
Total dividends collected$1.8K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BRLAF vs MRK ($10,000, DRIP)

YearBRLAF PortfolioBRLAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,181$481.03$11,206$366.19$25.00MRK
2$12,328$363.92$12,650$502.35$322.00MRK
3$13,462$271.49$14,407$694.19$945.00MRK
4$14,605$200.61$16,585$967.82$2.0KMRK
5$15,775$147.26$19,342$1,363.89$3.6KMRK
6$16,986$107.62$22,913$1,947.19$5.9KMRK
7$18,254$78.42$27,662$2,823.89$9.4KMRK
8$19,589$57.02$34,159$4,173.35$14.6KMRK
9$21,001$41.40$43,337$6,308.80$22.3KMRK
10$22,501$30.03$56,776$9,798.13$34.3KMRK

BRLAF vs MRK: Complete Analysis 2026

BRLAFStock

Our portfolio of high quality UK commercial property is focused on London Offices and Retail around the UK. We own or manage a portfolio valued at £13.7bn (British Land share: £10.3bn) as at 30 September 2020 making us one of Europe's largest listed real estate investment companies. Our strategy is to provide places which meet the needs of our customers and respond to changing lifestyles - Places People Prefer. We do this by creating great environments both inside and outside our buildings and use our scale and placemaking skills to enhance and enliven them. This expands their appeal to a broader range of occupiers, creating enduring demand and driving sustainable, long term performance. Our Offices portfolio comprises three office-led campuses in central London as well as high quality standalone buildings and accounts for 65% of our portfolio. Our Retail portfolio is focused on retail parks and shopping centres, and accounts for 31% of our portfolio. Increasingly our focus is on providing a mix of uses and this is most evident at Canada Water, our 53 acre redevelopment opportunity where we have plans to create a new neighbourhood for London. Sustainability is embedded throughout our business. Our places, which are designed to meet high sustainability standards, become part of local communities, provide opportunities for skills development and employment and promote wellbeing. In April 2016 British Land received the Queen's Award for Enterprise: Sustainable Development, the UK's highest accolade for business success for economic, social and environmental achievements over a period of five years.

Full BRLAF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BRLAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRLAF vs SCHDBRLAF vs JEPIBRLAF vs OBRLAF vs KOBRLAF vs MAINBRLAF vs JNJBRLAF vs ABBVBRLAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.